维普中文期刊产品整合服务

Guanxin Danshen Dripping Pills Improve Quality of Life and Cardiovascular Prognoses of CHD Patients after PCI with Anxiety or Depression(GLAD Study):A Randomized Double-Blind Placebo-Controlled Study

查看全文 作　　者：WANG Cheng-[1,2]long;HUAN [1,2]Na;WANG Pei-[1,2]li;GENG Qing-[3]shan;MA Wen-[4]lin;MA Li-[5]hong;JIANG Hong-[6]yan;MENG Xiao-[7]ping;ZHANG Da-[1,2]wu;GOU Xiao-[1,2]jiang;HU Da-[8]yi;CHEN Ke-[1,2]ji 高影响力作者 机构地区：[1]Department of Cardiovascular Disease,Xiyuan Hospital,Chinese Academy of Chinese Medical Sciences,Beijing(100091),China;[2]National Clinical Research Center for Chinese Medicine Cardiology,Beijing(100091),China;[3]Department of Cardiovascular Disease,Guangdong Provincial People’s Hospital,Guangzhou(510055)China;[4]Department of Cardiovascular Disease,Shanghai Tongji Hospital,Shanghai(200065),China;[5]Department of Cardiovascular Disease,Fuwai Hospital,Chinese Academy of Medical Sciences,Beijing(100037),China;[6]Department of Cardiovascular Disease,Beijing First Hospital of Integrated Chinese and Western Medicine,Beijing(100020),China;[7]Department of Cardiovascular Disease,Affiliated Hospital of Changchun University of Chinese Medicine,Changchun(130021),China;[8]Department of Cardiovascular Disease,People’s Hospital of Peking University,Beijing(100044),China高影响力机构 出　　处：《Chinese Journal of Integrative Medicine》索引2023年第29卷第3期,共10页高影响力期刊 摘　　要：Objective:To assess the efficacy and safety of Guanxin Danshen Dripping Pills(GXDS)in the treatment of depression or anxiety in patients with coronary heart disease(CHD)after percutaneous coronary intervention(PCI).Methods:From September 2017 to June 2019,200 CHD patients after PCI with depression and anxiety were included and randomly divided into GXDS(100 cases)and placebo control groups(100 cases)by block randomization and a random number table.Patients in the GXDS and control groups were given GXDS and placebo,respectively,0.4 g each time,3 times daily for 12 weeks.The primary outcomes were scores of Patient Health Questionnaire-9(PHQ-9),Generalized Anxiety Scale(GAD-7)and the Seattle Angina Pectoris Scale(SAQ).The secondary outcomes included 12 Health Survey Summary Form(SF-12)scores and the first onset time and incidence of major adverse cardiovascular events(MACEs).Other indices including blood pressure,blood lipids,microcirculation and inflammatory-related indices,etc.were monitored at baseline,week 4,and week 12.Results:In the full analysis set(200 cases),after treatment,the PHQ-9 and GAD-7 scores in the GXDS group were considerably lower than those in the control group(P<0.05).Compared with the baseline,the total PHQ-9 scores of the experimental and control groups decreased by 3.97 and 1.18,respectively.The corrected mean difference between the two groups was–2.78(95%CI:–3.47,–2.10;P<0.001).The total GAD-7 score in the GXDS group decreased by 3.48%compared with the baseline level,while that of the placebo group decreased by 1.13%.The corrected mean difference between the two groups was–2.35(95%CI:–2.95,–1.76;P<0.001).The degree of improvement in SAQ score,SF-12 score,endothelin and high-sensitive C-reactive protein levels in the GXDS group were substantially superior than those in the placebo group,and the differences between the two groups were statistically significant(P<0.05).Similar results were obtained in the per protocol population analysis of 177 patients.Three cases of MACES were reported in this study(1 in the GXDS group and 2 in the placebo group),and no serious adverse events occurred.Conclusions:GXDS can significantly alleviate depression and anxiety,relieve symptoms of angina,and improve quality of life in patients with CHD after PCI.(Registration No.ChiCTR1800014291) 关 键 词：Chinese medicine coronary heart disease percutaneous coronary intervention depression and anxiety state clinical efficacy
相关文献

参考文献(46)

引证文献(12)

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费